| Target Price | ¥4,437.00 |
| Price | ¥3,755.00 |
| Potential |
18.16%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Kaken Pharmaceutical Co 2027 .
The average Kaken Pharmaceutical Co target price is ¥4,437.00.
This is
18.16%
register free of charge
¥5,880.00
56.59%
register free of charge
¥4,040.00
7.59%
register free of charge
|
|
| A rating was issued by 8 analysts: 4 Analysts recommend Kaken Pharmaceutical Co to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Kaken Pharmaceutical Co stock has an average upside potential 2027 of
18.16%
register free of charge
|
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Revenue Billion ¥ | 76.87 | 91.51 |
| 18.25% | 19.04% | |
| EBITDA Margin | -0.19% | 13.84% |
| 100.84% | 7,337.38% | |
| Net Margin | 2.79% | 7.99% |
| 81.19% | 186.47% |
5 Analysts have issued a sales forecast Kaken Pharmaceutical Co 2027 . The average Kaken Pharmaceutical Co sales estimate is
This results in the following potential growth metrics:
5 Kaken Pharmaceutical Co Analysts have issued a net profit forecast 2027. The average Kaken Pharmaceutical Co net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Earnings Per Share ¥ | 56.55 | 192.98 |
| 84.52% | 241.26% | |
| P/E | 19.56 | |
| EV/Sales | 0.92 |
5 Analysts have issued a Kaken Pharmaceutical Co forecast for earnings per share. The average Kaken Pharmaceutical Co EPS is
This results in the following potential growth metrics and future valuations:
Kaken Pharmaceutical Co...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


